A detailed history of Nicholas Investment Partners, LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Nicholas Investment Partners, LP holds 18,807 shares of KRYS stock, worth $3.21 Million. This represents 0.38% of its overall portfolio holdings.

Number of Shares
18,807
Previous 17,327 8.54%
Holding current value
$3.21 Million
Previous $3.18 Million 7.51%
% of portfolio
0.38%
Previous 0.38%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$174.7 - $213.66 $258,555 - $316,216
1,480 Added 8.54%
18,807 $3.42 Million
Q2 2024

Aug 07, 2024

BUY
$153.12 - $183.64 $2.65 Million - $3.18 Million
17,327 New
17,327 $3.18 Million
Q4 2023

Feb 07, 2024

SELL
$96.0 - $128.29 $29.4 Million - $39.3 Million
-306,538 Reduced 86.2%
49,073 $6.09 Million
Q3 2023

Nov 13, 2023

SELL
$108.51 - $130.22 $2.1 Million - $2.52 Million
-19,340 Reduced 5.16%
355,611 $41.3 Million
Q2 2023

Aug 09, 2023

BUY
$78.48 - $130.32 $18,285 - $30,364
233 Added 0.06%
374,951 $44 Million
Q1 2023

May 11, 2023

BUY
$72.39 - $84.27 $7.79 Million - $9.07 Million
107,629 Added 40.3%
374,718 $30 Million
Q4 2022

Feb 10, 2023

BUY
$63.14 - $79.9 $2.85 Million - $3.6 Million
45,063 Added 20.3%
267,089 $21.2 Million
Q3 2022

Nov 14, 2022

SELL
$64.85 - $82.4 $379,437 - $482,122
-5,851 Reduced 2.57%
222,026 $15.5 Million
Q2 2022

Aug 10, 2022

SELL
$48.93 - $73.47 $41,835 - $62,816
-855 Reduced 0.37%
227,877 $15 Million
Q1 2022

May 10, 2022

BUY
$51.99 - $72.11 $1.95 Million - $2.7 Million
37,421 Added 19.56%
228,732 $15.2 Million
Q4 2021

Feb 14, 2022

SELL
$39.81 - $88.24 $2.61 Million - $5.79 Million
-65,564 Reduced 25.52%
191,311 $13.4 Million
Q3 2021

Nov 15, 2021

SELL
$52.01 - $71.77 $2.94 Million - $4.06 Million
-56,579 Reduced 18.05%
256,875 $13.4 Million
Q2 2021

Aug 10, 2021

BUY
$62.14 - $81.82 $544,657 - $717,152
8,765 Added 2.88%
313,454 $21.3 Million
Q1 2021

May 14, 2021

BUY
$59.42 - $85.46 $4.23 Million - $6.08 Million
71,146 Added 30.46%
304,689 $23.5 Million
Q4 2020

Feb 11, 2021

BUY
$40.64 - $61.38 $451,957 - $682,606
11,121 Added 5.0%
233,543 $14 Million
Q3 2020

Nov 13, 2020

BUY
$37.76 - $48.49 $6.91 Million - $8.87 Million
182,914 Added 462.98%
222,422 $9.58 Million
Q2 2020

Aug 12, 2020

SELL
$37.03 - $60.0 $1.57 Million - $2.54 Million
-42,408 Reduced 51.77%
39,508 $1.64 Million
Q1 2020

May 13, 2020

BUY
$35.02 - $65.64 $262,579 - $492,168
7,498 Added 10.08%
81,916 $3.54 Million
Q4 2019

Feb 13, 2020

SELL
$33.17 - $65.23 $1.17 Million - $2.31 Million
-35,409 Reduced 32.24%
74,418 $4.12 Million
Q3 2019

Nov 13, 2019

SELL
$34.72 - $51.3 $13,957 - $20,622
-402 Reduced 0.36%
109,827 $3.81 Million
Q2 2019

Aug 09, 2019

SELL
$27.2 - $41.2 $27,091 - $41,035
-996 Reduced 0.9%
110,229 $4.44 Million
Q1 2019

May 15, 2019

SELL
$19.86 - $32.9 $392,254 - $649,807
-19,751 Reduced 15.08%
111,225 $3.66 Million
Q4 2018

Feb 14, 2019

BUY
$15.03 - $25.38 $1.97 Million - $3.32 Million
130,976 New
130,976 $2.72 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.38B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Nicholas Investment Partners, LP Portfolio

Follow Nicholas Investment Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Nicholas Investment Partners, LP with notifications on news.